



NEWS RELEASE

MDxHealth Licenses Methylation Technology to Takara Bio Inc. for Scientific Research Market

DURHAM, NC, and LIEGE, BELGIUM – November 29, 2010 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc. (Tokyo Stock Exchange: 4974.T).

Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation technology, for the scientific research market in exchange for an upfront fee plus royalties from future sales utilizing this technology. Other terms were not disclosed.

Takara is an emerging global player in the market for research reagents, scientific instruments and contract research services based on cutting edge genetic engineering technologies. Takara's advanced capabilities increasingly also focus on DNA methylation.

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing for personalized medicine. The company's tests are based on patented gene methylation technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research center such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders.

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at <http://www.takara.com>.

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4 364 20 70

Hans Herklots
Capricorn One
+41 79 598 7149

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation